Pfizer $43 Billion Acquisition of Seagen
Introduction In a significant move within the pharmaceutical sector, Pfizer, the renowned U.S. pharmaceutical giant, has secured unconditional antitrust approval from the European Union for its proposed acquisition of Seagen, a prominent cancer drug manufacturer. The $43 billion deal, announced in March, has been a focal point in the industry, marking Pfizer’s substantial investment leveraging …